EADV 2026视频特辑｜Raj Chovatiya教授：2型炎症通路与炎症性皮肤病诊疗前沿进展

Raj Chovatiya 教授指出，特应性皮炎、结节性痒疹、慢性自发性荨麻疹、大疱性类天疱疮虽临床表现各不相同，但同属 2 型炎症介导的疾病家族，拥有相似的免疫失调机制。他对比了特应性皮炎与银屑病靶向治疗的不同现状：银屑病靶向治疗可实现皮损近乎清除，但特应性皮炎即便针对 2 型炎症通路，仍很难做到症状完全缓解；目前多特异性抗体尚处在探索阶段，靶点组合、安全有效性还有待验证，未来有望实现个体化精准治疗。此外他还阐述代谢和炎症性皮肤病存在双向关联，银屑病、化脓性汗腺炎和心血管代谢疾病密切相关，提出皮肤科临床需要重视肥胖、糖尿病等合并症，GLP‑1 类药物、运动及生活方式干预也会在皮肤科发挥更多作用。

Prof. Raj Chovatiya mentioned that atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria and bullous pemphigoid differ in clinical manifestations yet belong to a disease family driven by type‑2 inflammation with shared immune dysregulation. He compared targeted‑therapy outcomes between atopic dermatitis and psoriasis: targeted agents can achieve near‑complete skin clearance in psoriasis, whereas complete resolution remains hard to reach for atopic dermatitis even targeting type‑2 pathways. Multispecific antibodies are still in early exploration; target combinations, safety and efficacy remain to be validated for future personalized precise treatment. He also addressed the bidirectional interplay between metabolism and inflammatory skin diseases. Conditions such as psoriasis and hidradenitis suppurativa are closely linked to cardiometabolic disorders. He highlighted that dermatologists should pay attention to comorbidities like obesity and diabetes, and GLP‑1 agents together with lifestyle and exercise interventions will play an expanding role in dermatology practice.